While it remains to be seen whether this sensitizing mechanism is conserved between cancer types, these results are further evidence that clinically approved HDAC inhibitors may improve clinical efficacy of TRAIL therapies, including gene therapy. This evidence concerns the gene TNFSF10 and cancer.